Key facts
- Net profit rose 62.4% to 19.16 billion yuan in the first nine months of 2026.
- Revenue increased 38.6% year-on-year to 45.54 billion yuan.
- Full-year revenue guidance raised to 61.0-61.9 billion yuan.
WuXi AppTec raised its full-year revenue guidance after reporting a 62.4% surge in net profit for the first nine months of 2026. Revenue increased 38.6% year-on-year, driven by strong demand for its drug development and manufacturing services. The Chinese pharmaceutical research services provider's net profit reached 19.16 billion yuan (US$2.87 billion) for the nine months ended September 30, compared with 11.80 billion yuan a year earlier. The company further raised its full-year revenue target to RMB 61.0-61.9 billion, previously RMB 58.5-60.5 billion.